Researchers should consult the primary literature and follow their institution's research protocols
Clinical Impact: Clinical studies and patient observations have shown that GLP-1 agonists can lead to substantial weight loss in individuals with severe obesity, including those with genetic syndromes like BBS
The STEP 2 study, a randomized, double-blind, double-dummy, placebo-controlled phase 3 clinical trial reported in The Lancet , involved more than 1,200 adults with Type 2 diabetes who were overweight or obese at the time
#Healthcare #GLP1 #ObesityCare #Type2Diabetes #PreventiveMedicine #LongevityMedicine #DigitalHealth #MedicalInnovation #HealthcareInnovation #Medicine #HealthTech #EvidenceBasedMedicine To view or add a comment, sign in Obesity management is evolving
According to the October 2024 multi-society guidance from the American Society of Anesthesiologists (ASA), American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE), and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), most patients can safely continue their GLP-1 medications before elective procedures with appropriate risk mitigation strategies
They help the body perform and regulate a wide range of physiological processes necessary for good health and wellbeing
